12-24-2025, 03:02 AM
I've been closely following the recent CRISPR gene editing breakthroughs, particularly the early-stage clinical trials for sickle cell disease and beta-thalassemia, and the results seem almost too good to be true. As a researcher in a related field, I'm thrilled by the potential, but I'm also concerned about the long-term safety data and the accessibility of these incredibly expensive therapies. The recent news about using base editing to target cholesterol levels in vivo is another huge leap. For others tracking this space, what do you see as the most significant technical or ethical hurdle that needs to be overcome for the next wave of applications, especially for more common polygenic conditions? Are there any under-discussed risks, like unintended epigenetic effects or immune responses to the editing machinery, that the field should be prioritizing in preclinical models?